ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

17 May 2021 13:05:01 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

10 May 2021 04:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

21 Apr 2021 13:05:00 By Nasdaq GlobeNewswire

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

05 Apr 2021 04:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

18 Mar 2021 13:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors

15 Mar 2021 04:00:02 By Nasdaq GlobeNewswire

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

04 Mar 2021 13:05:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference

02 Mar 2021 04:00:02 By Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

11 Jan 2021 04:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 04:00:00 By Nasdaq GlobeNewswire